Inhibition of Protein Synthesis by Y Box-Binding Protein 1 Blocks Oncogenic Cell Transformation

REFERENCES

• Aoki, M., O. Batista, A. Bellacosa, P. Tsichlis, and P. K. Vogt. 1998. The akt kinase: molecular determinants of oncogenicity. Proc. Natl. Acad. Sci. USA 95:14950–14955.
   PubMed Web of Science ®Google Scholar
• Aoki, M., E. Blazek, and P. K. Vogt. 2001. A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc. Natl. Acad. Sci. USA 98:136–141.
   PubMed Web of Science ®Google Scholar
• Aoki, M., C. Schetter, M. Himly, O. Batista, H. W. Chang, and P. K. Vogt. 2000. The catalytic subunit of phosphoinositide 3-kinase: requirements for oncogenicity. J. Biol. Chem. 275:6267–6275.
   PubMed Web of Science ®Google Scholar
• Aoki, M., V. Sobek, D. J. Maslyar, A. Hecht, and P. K. Vogt. 2002. Oncogenic transformation by beta-catenin: deletion analysis and characterization of selected target genes. Oncogene 21:6983–6991.
   PubMed Web of Science ®Google Scholar
• Bader, A. G., K. A. Felts, N. Jiang, H. W. Chang, and P. K. Vogt. 2003. Y box-binding protein 1 induces resistance to oncogenic transformation by the phosphatidylinositol 3-kinase pathway. Proc. Natl. Acad. Sci. USA 100:12384–12389.
   PubMed Web of Science ®Google Scholar
• Bader, A. G., M. Hartl, and K. Bister. 2000. Conditional cell transformation by doxycycline-controlled expression of the ASV17 v-jun allele. Virology 270:98–110.
   PubMedGoogle Scholar
• Bader, A. G., and P. K. Vogt. 2004. An essential role for protein synthesis in oncogenic cellular transformation. Oncogene 23:3145–3150.
   PubMedGoogle Scholar
• Barash, I. 1999. Prolactin and insulin synergize to regulate the translation modulator PHAS-I via mitogen-activated protein kinase-independent but wortmannin- and rapamycin-sensitive pathway. Mol. Cell. Endocrinol. 155:37–49.
   PubMedGoogle Scholar
• Barrieux, A., H. A. Ingraham, S. Nystul, and M. G. Rosenfeld. 1976. Characterization of the association of specific proteins with messenger ribonucleic acid. Biochemistry 15:3523–3528.
   PubMed Web of Science ®Google Scholar
• Bellacosa, A., D. de Feo, A. K. Godwin, D. W. Bell, J. Q. Cheng, D. A. Altomare, M. Wan, L. Dubeau, G. Scambia, V. Masciullo, et al. 1995. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int. J. Cancer 64:280–285.
   PubMed Web of Science ®Google Scholar
• Bellacosa, A., J. R. Testa, S. P. Staal, and P. N. Tsichlis. 1991. A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science 254:274–277.
   PubMed Web of Science ®Google Scholar
• Blobel, G. 1972. Protein tightly bound to globin mRNA. Biochem. Biophys. Res. Commun. 47:88–95.
   PubMed Web of Science ®Google Scholar
• Cantley, L. C., and B. G. Neel. 1999. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc. Natl. Acad. Sci. USA 96:4240–4245.
   PubMed Web of Science ®Google Scholar
• Chang, H. W., M. Aoki, D. Fruman, K. R. Auger, A. Bellacosa, P. N. Tsichlis, L. C. Cantley, T. M. Roberts, and P. K. Vogt. 1997. Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase. Science 276:1848–1850.
   PubMed Web of Science ®Google Scholar
• Cheng, J. Q., A. K. Godwin, A. Bellacosa, T. Taguchi, T. F. Franke, T. C. Hamilton, P. N. Tsichlis, and J. R. Testa. 1992. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc. Natl. Acad. Sci. USA 89:9267–9271.
   PubMed Web of Science ®Google Scholar
• Corradetti, M. N., K. Inoki, N. Bardeesy, R. A. DePinho, and K. L. Guan. 2004. Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes Dev. 18:1533–1538.
   PubMed Web of Science ®Google Scholar
• Devroede, G., B. Lemieux, S. Masse, J. Lamarche, and P. S. Herman. 1988. Colonic hamartomas in tuberous sclerosis. Gastroenterology 94:182–188.
   PubMedGoogle Scholar
• Dingwall, C., and R. A. Laskey. 1991. Nuclear targeting sequences—a consensus. Trends Biochem. Sci. 16:478–481.
   PubMed Web of Science ®Google Scholar
• Evdokimova, V., P. Ruzanov, H. Imataka, B. Raught, Y. Svitkin, L. P. Ovchinnikov, and N. Sonenberg. 2001. The major mRNA-associated protein YB-1 is a potent 5′ cap-dependent mRNA stabilizer. EMBO J. 20:5491–5502.
   PubMed Web of Science ®Google Scholar
• Evdokimova, V. M., and L. P. Ovchinnikov. 1999. Translational regulation by Y-box transcription factor: involvement of the major mRNA-associated protein, p50. Int. J. Biochem. Cell Biol. 31:139–149.
   PubMedGoogle Scholar
• Fornerod, M., M. Ohno, M. Yoshida, and I. W. Mattaj. 1997. CRM1 is an export receptor for leucine-rich nuclear export signals. Cell 90:1051–1060.
   PubMed Web of Science ®Google Scholar
• Freedman, D. A., and A. J. Levine. 1998. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol. Cell. Biol. 18:7288–7293.
   PubMed Web of Science ®Google Scholar
• Fukada, T., and N. K. Tonks. 2003. Identification of YB-1 as a regulator of PTP1B expression: implications for regulation of insulin and cytokine signaling. EMBO J. 22:479–493.
   PubMedGoogle Scholar
• Fukuchi-Shimogori, T., I. Ishii, K. Kashiwagi, H. Mashiba, H. Ekimoto, and K. Igarashi. 1997. Malignant transformation by overproduction of translation initiation factor eIF4G. Cancer Res. 57:5041–5044.
   PubMed Web of Science ®Google Scholar
• Gaudreault, I., D. Guay, and M. Lebel. 2004. YB-1 promotes strand separation in vitro of duplex DNA containing either mispaired bases or cisplatin modifications, exhibits endonucleolytic activities and binds several DNA repair proteins. Nucleic Acids Res. 32:316–327.
   PubMed Web of Science ®Google Scholar
• Gebauer, F., and M. W. Hentze. 2004. Molecular mechanisms of translational control. Nat. Rev. Mol. Cell Biol. 5:827–835.
   PubMed Web of Science ®Google Scholar
• Gessner, C., C. Woischwill, A. Schumacher, U. Liebers, H. Kuhn, P. Stiehl, K. Jurchott, H. D. Royer, C. Witt, and G. Wolff. 2004. Nuclear YB-1 expression as a negative prognostic marker in non-small cell lung cancer. Eur. Respir. J. 23:14–19.
   PubMed Web of Science ®Google Scholar
• Graff, J. R., and S. G. Zimmer. 2003. Translational control and metastatic progression: enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs. Clin. Exp. Metastasis 20:265–273.
   PubMed Web of Science ®Google Scholar
• Hay, N., and N. Sonenberg. 2004. Upstream and downstream of mTOR. Genes Dev. 18:1926–1945.
   PubMed Web of Science ®Google Scholar
• Hemminki, A., D. Markie, I. Tomlinson, E. Avizienyte, S. Roth, A. Loukola, G. Bignell, W. Warren, M. Aminoff, P. Hoglund, H. Jarvinen, P. Kristo, K. Pelin, M. Ridanpaa, R. Salovaara, T. Toro, W. Bodmer, S. Olschwang, A. S. Olsen, M. R. Stratton, A. de la Chapelle, and L. A. Aaltonen. 1998. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 391:184–187.
   PubMed Web of Science ®Google Scholar
• Huang, T. T., N. Kudo, M. Yoshida, and S. Miyamoto. 2000. A nuclear export signal in the N-terminal regulatory domain of IκBα controls cytoplasmic localization of inactive NF-κB/IκBα complexes. Proc. Natl. Acad. Sci. USA 97:1014–1019.
   PubMed Web of Science ®Google Scholar
• Hughes, S. H., J. J. Greenhouse, C. J. Petropoulos, and P. Sutrave. 1987. Adaptor plasmids simplify the insertion of foreign DNA into helper-independent retroviral vectors. J. Virol. 61:3004–3012.
   PubMed Web of Science ®Google Scholar
• Inoki, K., Y. Li, T. Xu, and K. L. Guan. 2003. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 17:1829–1834.
   PubMed Web of Science ®Google Scholar
• Inoki, K., Y. Li, T. Zhu, J. Wu, and K. L. Guan. 2002. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 4:648–657.
   PubMed Web of Science ®Google Scholar
• Izumi, H., T. Imamura, G. Nagatani, T. Ise, T. Murakami, H. Uramoto, T. Torigoe, H. Ishiguchi, Y. Yoshida, M. Nomoto, T. Okamoto, T. Uchiumi, M. Kuwano, K. Funa, and K. Kohno. 2001. Y box-binding protein-1 binds preferentially to single-stranded nucleic acids and exhibits 3′→5′ exonuclease activity. Nucleic Acids Res. 29:1200–1207.
   PubMedGoogle Scholar
• Janz, M., N. Harbeck, P. Dettmar, U. Berger, A. Schmidt, K. Jurchott, M. Schmitt, and H. D. Royer. 2002. Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1. Int. J. Cancer 97:278–282.
   PubMedGoogle Scholar
• Jefferies, H. B., S. Fumagalli, P. B. Dennis, C. Reinhard, R. B. Pearson, and G. Thomas. 1997. Rapamycin suppresses 5′TOP mRNA translation through inhibition of p70s6k. EMBO J. 16:3693–3704.
   PubMed Web of Science ®Google Scholar
• Jurchott, K., S. Bergmann, U. Stein, W. Walther, M. Janz, I. Manni, G. Piaggio, E. Fietze, M. Dietel, and H. D. Royer. 2003. YB-1 as a cell cycle-regulated transcription factor facilitating cyclin A and cyclin B1 gene expression. J. Biol. Chem. 278:27988–27996.
   PubMedGoogle Scholar
• Kalderon, D., W. D. Richardson, A. F. Markham, and A. E. Smith. 1984. Sequence requirements for nuclear location of simian virus 40 large-T antigen. Nature 311:33–38.
   PubMed Web of Science ®Google Scholar
• Kalderon, D., B. L. Roberts, W. D. Richardson, and A. E. Smith. 1984. A short amino acid sequence able to specify nuclear location. Cell 39:499–509.
   PubMed Web of Science ®Google Scholar
• Koike, K., T. Uchiumi, T. Ohga, S. Toh, M. Wada, K. Kohno, and M. Kuwano. 1997. Nuclear translocation of the Y-box binding protein by ultraviolet irradiation. FEBS Lett. 417:390–394.
   PubMed Web of Science ®Google Scholar
• Kudo, N., B. Wolff, T. Sekimoto, E. P. Schreiner, Y. Yoneda, M. Yanagida, S. Horinouchi, and M. Yoshida. 1998. Leptomycin B inhibition of signal-mediated nuclear export by direct binding to CRM1. Exp. Cell. Res. 242:540–547.
   PubMed Web of Science ®Google Scholar
• Lazaris-Karatzas, A., K. S. Montine, and N. Sonenberg. 1990. Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5′ cap. Nature 345:544–547.
   PubMed Web of Science ®Google Scholar
• Lin, T. A., X. Kong, T. A. Haystead, A. Pause, G. Belsham, N. Sonenberg, and J. C. Lawrence, Jr. 1994. PHAS-I as a link between mitogen-activated protein kinase and translation initiation. Science 266:653–656.
   PubMed Web of Science ®Google Scholar
• Lynch, M., C. Fitzgerald, K. A. Johnston, S. Wang, and E. V. Schmidt. 2004. Activated eIF4E-binding protein slows G1 progression and blocks transformation by c-myc without inhibiting cell growth. J. Biol. Chem. 279:3327–3339.
   PubMed Web of Science ®Google Scholar
• Ma, Y. Y., S. J. Wei, Y. C. Lin, J. C. Lung, T. C. Chang, J. Whang-Peng, J. M. Liu, D. M. Yang, W. K. Yang, and C. Y. Shen. 2000. PIK3CA as an oncogene in cervical cancer. Oncogene 19:2739–2744.
   PubMed Web of Science ®Google Scholar
• Mende, I., S. Malstrom, P. N. Tsichlis, P. K. Vogt, and M. Aoki. 2001. Oncogenic transformation induced by membrane-targeted Akt2 and Akt3. Oncogene 20:4419–4423.
   PubMedGoogle Scholar
• Mertens, P. R., S. Harendza, A. S. Pollock, and D. H. Lovett. 1997. Glomerular mesangial cell-specific transactivation of matrix metalloproteinase 2 transcription is mediated by YB-1. J. Biol. Chem. 272:22905–22912.
   PubMed Web of Science ®Google Scholar
• Minich, W. B., and L. P. Ovchinnikov. 1992. Role of cytoplasmic mRNP proteins in translation. Biochimie 74:477–483.
   PubMed Web of Science ®Google Scholar
• Miwa, W., J. Yasuda, Y. Murakami, K. Yashima, K. Sugano, T. Sekine, A. Kono, S. Egawa, K. Yamaguchi, Y. Hayashizaki, and T. Sekiya. 1996. Isolation of DNA sequences amplified at chromosome 19q13.1-q13.2 including the AKT2 locus in human pancreatic cancer. Biochem. Biophys. Res. Commun. 225:968–974.
   PubMedGoogle Scholar
• Montagne, J., T. Radimerski, and G. Thomas. 2001. Insulin signaling: lessons from the Drosophila tuberous sclerosis complex, a tumor suppressor. Sci. STKE 2001:PE36.
   PubMedGoogle Scholar
• Nekrasov, M. P., M. P. Ivshina, K. G. Chernov, E. A. Kovrigina, V. M. Evdokimova, A. A. Thomas, J. W. Hershey, and L. P. Ovchinnikov. 2003. The mRNA-binding protein YB-1 (p50) prevents association of the eukaryotic initiation factor eIF4G with mRNA and inhibits protein synthesis at the initiation stage. J. Biol. Chem. 278:13936–13943.
   PubMed Web of Science ®Google Scholar
• Neshat, M. S., I. K. Mellinghoff, C. Tran, B. Stiles, G. Thomas, R. Petersen, P. Frost, J. J. Gibbons, H. Wu, and C. L. Sawyers. 2001. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. USA 98:10314–10319.
   PubMed Web of Science ®Google Scholar
• Norman, J. T., G. E. Lindahl, K. Shakib, A. En-Nia, E. Yilmaz, and P. R. Mertens. 2001. The Y-box binding protein YB-1 suppresses collagen alpha 1(I) gene transcription via an evolutionarily conserved regulatory element in the proximal promoter. J. Biol. Chem. 276:29880–29890.
   PubMedGoogle Scholar
• Ohga, T., T. Uchiumi, Y. Makino, K. Koike, M. Wada, M. Kuwano, and K. Kohno. 1998. Direct involvement of the Y-box binding protein YB-1 in genotoxic stress-induced activation of the human multidrug resistance 1 gene. J. Biol. Chem. 273:5997–6000.
   PubMed Web of Science ®Google Scholar
• Pandolfi, P. P. E. 2004. Translation and cancer. Oncogene 23:3134–3248.
   PubMed Web of Science ®Google Scholar
• Pisarev, A. V., M. A. Skabkin, A. A. Thomas, W. C. Merrick, L. P. Ovchinnikov, and I. N. Shatsky. 2002. Positive and negative effects of the major mammalian messenger ribonucleoprotein p50 on binding of 40S ribosomal subunits to the initiation codon of beta-globin mRNA. J. Biol. Chem. 277:15445–15451.
   PubMed Web of Science ®Google Scholar
• Podsypanina, K., R. T. Lee, C. Politis, I. Hennessy, A. Crane, J. Puc, M. Neshat, H. Wang, L. Yang, J. Gibbons, P. Frost, V. Dreisbach, J. Blenis, Z. Gaciong, P. Fisher, C. Sawyers, L. Hedrick-Ellenson, and R. Parsons. 2001. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/− mice. Proc. Natl. Acad. Sci. USA 98:10320–10325.
   PubMed Web of Science ®Google Scholar
• Raffetseder, U., B. Frye, T. Rauen, K. Jurchott, H. D. Royer, P. L. Jansen, and P. R. Mertens. 2003. Splicing factor SRp30c interaction with Y-box protein-1 confers nuclear YB-1 shuttling and alternative splice site selection. J. Biol. Chem. 278:18241–19248.
   PubMedGoogle Scholar
• Rajasekhar, V. K., A. Viale, N. D. Socci, M. Wiedmann, X. Hu, and E. C. Holland. 2003. Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. Mol. Cell 12:889–901.
   PubMed Web of Science ®Google Scholar
• Ranjan, M., S. R. Tafuri, and A. P. Wolffe. 1993. Masking mRNA from translation in somatic cells. Genes Dev. 7:1725–1736.
   PubMed Web of Science ®Google Scholar
• Ruggeri, B. A., L. Huang, M. Wood, J. Q. Cheng, and J. R. Testa. 1998. Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Mol. Carcinog. 21:81–86.
   PubMed Web of Science ®Google Scholar
• Ruggero, D., L. Montanaro, L. Ma, W. Xu, P. Londei, C. Cordon-Cardo, and P. P. Pandolfi. 2004. The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat. Med. 10:484–486.
   PubMed Web of Science ®Google Scholar
• Samuels, Y., Z. Wang, A. Bardelli, N. Silliman, J. Ptak, S. Szabo, H. Yan, A. Gazdar, S. M. Powell, G. J. Riggins, J. K. Willson, S. Markowitz, K. W. Kinzler, B. Vogelstein, and V. E. Velculescu. 2004. High frequency of mutations of the PIK3CA gene in human cancers. Science 304:554.
   PubMed Web of Science ®Google Scholar
• Shaw, R. J., N. Bardeesy, B. D. Manning, L. Lopez, M. Kosmatka, R. A. DePinho, and L. C. Cantley. 2004. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 6:91–99.
   PubMed Web of Science ®Google Scholar
• Shibahara, K., K. Sugio, T. Osaki, T. Uchiumi, Y. Maehara, K. Kohno, K. Yasumoto, K. Sugimachi, and M. Kuwano. 2001. Nuclear expression of the Y-box binding protein, YB-1, as a novel marker of disease progression in non-small cell lung cancer. Clin. Cancer Res. 7:3151–3155.
   PubMed Web of Science ®Google Scholar
• Simpson, L., and R. Parsons. 2001. PTEN: life as a tumor suppressor. Exp. Cell. Res. 264:29–41.
   PubMed Web of Science ®Google Scholar
• Sommerville, J., and M. Ladomery. 1996. Masking of mRNA by Y-box proteins. FASEB J. 10:435–443.
   PubMedGoogle Scholar
• Sonderegger, C. K., M. Narisawa-Saito, and P. K. Vogt. 2003. The C-terminal region of cellular Qin oligomerizes: correlation with oncogenic transformation and transcriptional repression. Oncogene 22:1908–1915.
   PubMedGoogle Scholar
• Staal, S. P., and J. W. Hartley. 1988. Thymic lymphoma induction by the AKT8 murine retrovirus. J. Exp. Med. 167:1259–1264.
   PubMed Web of Science ®Google Scholar
• Staal, S. P., J. W. Hartley, and W. P. Rowe. 1977. Isolation of transforming murine leukemia viruses from mice with a high incidence of spontaneous lymphoma. Proc. Natl. Acad. Sci. USA 74:3065–3067.
   PubMed Web of Science ®Google Scholar
• Stade, K., C. S. Ford, C. Guthrie, and K. Weis. 1997. Exportin 1 (Crm1p) is an essential nuclear export factor. Cell 90:1041–1050.
   PubMed Web of Science ®Google Scholar
• Stenina, O. I., K. M. Shaneyfelt, and P. E. DiCorleto. 2001. Thrombin induces the release of the Y-box protein dbpB from mRNA: a mechanism of transcriptional activation. Proc. Natl. Acad. Sci. USA 98:7277–7282.
   PubMed Web of Science ®Google Scholar
• Stolovich, M., H. Tang, E. Hornstein, G. Levy, R. Cohen, S. S. Bae, M. J. Birnbaum, and O. Meyuhas. 2002. Transduction of growth or mitogenic signals into translational activation of TOP mRNAs is fully reliant on the phosphatidylinositol 3-kinase-mediated pathway but requires neither S6K1 nor rpS6 phosphorylation. Mol. Cell. Biol. 22:8101–8113.
   PubMedGoogle Scholar
• Swamynathan, S. K., B. R. Varma, K. T. Weber, and R. V. Guntaka. 2002. Targeted disruption of one allele of the Y-box protein gene, Chk-YB-1b, in DT40 cells results in major defects in cell cycle. Biochem. Biophys. Res. Commun. 296:451–457.
   PubMedGoogle Scholar
• Thomas, G., D. M. Sabatini, and N. M. Hall (ed.). 2004. TOR—target of rapamycin. Current topics in microbiology and immunology, vol. 279. Springer, Berlin, Germany.
   Google Scholar
• Ting, J. P., A. Painter, N. J. Zeleznik-Le, G. MacDonald, T. M. Moore, A. Brown, and B. D. Schwartz. 1994. YB-1 DNA-binding protein represses interferon gamma activation of class II major histocompatibility complex genes. J. Exp. Med. 179:1605–1611.
   PubMedGoogle Scholar
• Uramoto, H., H. Izumi, T. Ise, M. Tada, T. Uchiumi, M. Kuwano, K. Yasumoto, K. Funa, and K. Kohno. 2002. p73 Interacts with c-Myc to regulate Y-box-binding protein-1 expression. J. Biol. Chem. 277:31694–31702.
   PubMed Web of Science ®Google Scholar
• Vivanco, I., and C. L. Sawyers. 2002. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer 2:489–501.
   PubMed Web of Science ®Google Scholar
• Vogt, P. K. 1969. Focus assay of Rous sarcoma virus, p. 198–211. In K. Habel and N. P. Salzman (ed.), Fundamental techniques in virology. Academic Press, New York, N.Y.
   Google Scholar
• Yahata, H., H. Kobayashi, T. Kamura, S. Amada, T. Hirakawa, K. Kohno, M. Kuwano, and H. Nakano. 2002. Increased nuclear localization of transcription factor YB-1 in acquired cisplatin-resistant ovarian cancer. J. Cancer Res. Clin. Oncol. 128:621–626.
   PubMedGoogle Scholar
• Yang, H. S., A. P. Jansen, A. A. Komar, X. Zheng, W. C. Merrick, S. Costes, S. J. Lockett, N. Sonenberg, and N. H. Colburn. 2003. The transformation suppressor Pdcd4 is a novel eukaryotic translation initiation factor 4A binding protein that inhibits translation. Mol. Cell. Biol. 23:26–37.
   PubMed Web of Science ®Google Scholar
• Yang, J., E. S. Bardes, J. D. Moore, J. Brennan, M. A. Powers, and S. Kornbluth. 1998. Control of cyclin B1 localization through regulated binding of the nuclear export factor CRM1. Genes Dev. 12:2131–2143.
   PubMed Web of Science ®Google Scholar
• Zasedateleva, O. A., A. S. Krylov, D. V. Prokopenko, M. A. Skabkin, L. P. Ovchinnikov, A. Kolchinsky, and A. D. Mirzabekov. 2002. Specificity of mammalian Y-box binding protein p50 in interaction with ss and ds DNA analyzed with generic oligonucleotide microchip. J. Mol. Biol. 324:73–87.
   PubMedGoogle Scholar
• Zhang, Y. F., C. Homer, S. J. Edwards, L. Hananeia, A. Lasham, J. Royds, P. Sheard, and A. W. Braithwaite. 2003. Nuclear localization of Y-box factor YB1 requires wild-type p53. Oncogene 22:2782–2794.
   PubMed Web of Science ®Google Scholar